Compare Main Street Capital Corporation (MAIN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Moderna, Inc. — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.07B), while Moderna, Inc. trades at $196.71 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 15.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.87% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Moderna, Inc. for 59 Days on average.
| MAIN | MRNA | |
|---|---|---|
Market Cap | $5.07B | $78.44B |
Volume | 685,683 | 14,597,511 |
Sector | Financials | Health |
52-Week High | $64.60 | $203.46 |
52-Week Low | $49.63 | $22.36 |
Typical Hold Time | 88 Days | 59 Days |
Enterprise Value | $7.51B | $74.59B |
Dividend Yield | 5.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with an 80.77% net income margin. Recent news highlights MAIN's status as a top-tier BDC with a well-covered monthly dividend, though some analysts cite valuation concerns amid rising Treasury yields.
Outlook remains cautiously optimistic given MAIN's robust fundamentals and dividend track record, but near-term headwinds include earnings volatility and premium valuation risks. The stock offers income appeal with a 7.9%+ yield, yet investors face pressure from technical weakness and macroeconomic sensitivity.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
